- The FDA approved Pfizer Inc’s (NYSE:PFE) TICOVAC (tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals one year of age and older.
- TICOVAC was developed using a master ‘seed’ virus similar to the TBE virus found in nature. It can induce neutralizing antibodies against the natural TBE virus, as the sequence and structure of the virus subtype match those found in nature.
- TICOVAC is the only FDA-approved vaccine to help protect U.S. adults and children against the TBE virus when visiting or living in TBE endemic areas.
- Tick-borne encephalitis is a common tick-borne disease in Europe, along with Lyme borreliosis.
- “This vaccine has helped to protect millions of people in TBE endemic regions since its first approval outside the U.S. 45 years ago.”
- TBE is a viral infection of the brain and spine, which can be transmitted to humans through the bite of an infected tick.
- Price Action: PFE shares are down 0.31% at $48.31 during the premarket session on the last check Monday.
- Related content: Benzinga’s Full FDA Calendar
Morgan Stanley Maintains Equal-Weight on Oracle, Raises Price Target to $88
Morgan Stanley analyst Keith Weiss maintains Oracle (NYSE:ORCL) with a Equal-Weight and raises the price target from $87 to $88.
